Damora Therapeutics annual current ratio
2019
2020
2021
2022
2023
2024
2025
Damora Therapeutics Current Ratio Growth & History (DMRA)
Damora Therapeutics's current ratio was 12.98 for fiscal 2025.
View full Damora Therapeutics company overviewDamora Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 12.98 | −1.09 | −7.74% |
| 2024 | 2024-12-31 | 14.07 | 7.76 | +123.02% |
| 2023 | 2023-12-31 | 6.31 | 0.55 | +9.62% |
| 2022 | 2022-12-31 | 5.75 | −18.48 | −76.25% |
| 2021 | 2021-12-31 | 24.23 | −6.19 | −20.34% |
| 2020 | 2020-12-31 | 30.42 | 23.34 | +329.93% |
| 2019 | 2019-12-31 | 7.07 | — | — |
Damora Therapeutics quarterly current ratio
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 19.73 | 14.78 | +298.19% |
| Q1 2026 | 2026-03-31 | 22.48 | 12.86 | +133.69% |
| Q4 2025 | 2025-12-31 | 12.98 | −1.09 | −7.74% |
| Q3 2025 | 2025-09-30 | 3.73 | −4.95 | −57.00% |
| Q2 2025 | 2025-06-30 | 4.96 | −1.83 | −26.98% |
| Q1 2025 | 2025-03-31 | 9.62 | 2.55 | +36.03% |
| Q4 2024 | 2024-12-31 | 14.07 | 7.76 | +123.02% |
| Q3 2024 | 2024-09-30 | 8.68 | 4.93 | +131.49% |
| Q2 2024 | 2024-06-30 | 6.79 | 3.07 | +82.59% |
| Q1 2024 | 2024-03-31 | 7.07 | 3.01 | +74.11% |
| Q4 2023 | 2023-12-31 | 6.31 | 0.55 | +9.62% |
| Q3 2023 | 2023-09-30 | 3.75 | −4.29 | −53.37% |
| Q2 2023 | 2023-06-30 | 3.72 | −7.26 | −66.15% |
| Q1 2023 | 2023-03-31 | 4.06 | −9.39 | −69.80% |
| Q4 2022 | 2022-12-31 | 5.75 | −18.48 | −76.25% |
| Q3 2022 | 2022-09-30 | 8.04 | −10.59 | −56.86% |
| Q2 2022 | 2022-06-30 | 10.98 | −11.67 | −51.54% |
| Q1 2022 | 2022-03-31 | 13.45 | −7.65 | −36.26% |
| Q4 2021 | 2021-12-31 | 24.23 | −6.19 | −20.34% |
| Q3 2021 | 2021-09-30 | 18.63 | 7.02 | +60.49% |
| Q2 2021 | 2021-06-30 | 22.65 | — | — |
| Q1 2021 | 2021-03-31 | 21.10 | — | — |
| Q4 2020 | 2020-12-31 | 30.42 | 23.34 | +329.93% |
| Q3 2020 | 2020-09-30 | 11.61 | — | — |
| Q4 2019 | 2019-12-31 | 7.07 | — | — |
Damora Therapeutics current ratio trends
Over the last five fiscal years, Damora Therapeutics's current ratio decreased from 30.42 to 12.98, a change of −17.44. The latest reported quarter, Q2 2026, shows 19.73.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Damora Therapeutics source filings ↗